Christina S. Turn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christina S. Turn has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Michael D. Hogarty
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
3 shared publications Annette Vu
Division of Oncology and Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, USA
2 shared publicationsCara Toland
Division of Oncology and Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia - USA
2 shared publicationsCaroline Eigenmann
Pediatric Cancer Metabolism Laboratory, Children’s Research Center, University of Zurich, Zurich, Switzerland
2 shared publications- Eileen White
Rutgers Cancer Institute, Rutgers University, New Brunswick, USA
2 shared publications George E. Allen
Bioinformatics Support Platform, Faculty of Medicine, Geneva, Switzerland
2 shared publications
Latest Publications
- 2 September 2026
- Published by American Society of Hematology in Blood
Multimodal analysis of CD38 in T-cell Acute Lymphoblastic Leukemia Identifies Combinatorial Therapeutic Strategies
Outcomes for pediatric patients with refractory or relapsed T-cell acute lymphoblastic leukemia (T-ALL) are poor, underscoring the need for improved therapeutic strategies. CD38, a type II transmembrane glycoprotein, is a promising target in T-ALL, with clinical trials evaluating CD38-targeting immunotherapies in frontline and relapsed settings. However, the biological role of CD38 in T-ALL has not been systematically defined. We interrogated CD38 biology through multimodal profiling of pediatric T-ALL samples. Bulk RNA sequencing of 1,335 primary tumors revealed that CD38 expression varies across genomic and immunophenotypic subtypes in T-ALL. Flow cytometry of 150 primary samples and CITE-sequencing of 40 cases demonstrated broad surface expression of CD38. A transcription factor CRISPR-screen identified RUNX1, RUNX3, and TP53 as candidate positive regulators of CD38. Metabolomic profiling of cell lines further revealed disruption of the polyamine pathway following CD38 perturbation. Supporting this finding, co-targeting CD38 with difluoromethylornithine (DFMO), a polyamine metabolism disruptor, improved survival in preclinical models. Across transcriptomic datasets, including primary tumors, cell lines, and patient-derived xenograft models, IL32 expression consistently decreased following CD38 loss or negativity, supporting an association between CD38 and inflammatory signaling pathways. Additionally, CD38 and LCK expression were positively correlated across majority of genomic subtypes, implicating SRC kinase signaling. Consistent with this, daratumumab in cell lines increased LCK phosphorylation, and combination therapy with dasatinib improved survival compared to monotherapy. Collectively, these findings define previously unrecognized interactions between CD38 and targetable pathways and genes in T-ALL and identify rational combinatorial strategies to enhance CD38-directed therapies and reduce relapse risk.
- 2 September 2026
- Published by American Society of Hematology in Blood
Multimodal analysis of CD38 in T-cell Acute Lymphoblastic Leukemia Identifies Combinatorial Therapeutic Strategies
Outcomes for pediatric patients with refractory or relapsed T-cell acute lymphoblastic leukemia (T-ALL) are poor, underscoring the need for improved therapeutic strategies. CD38, a type II transmembrane glycoprotein, is a promising target in T-ALL, with clinical trials evaluating CD38-targeting immunotherapies in frontline and relapsed settings. However, the biological role of CD38 in T-ALL has not been systematically defined. We interrogated CD38 biology through multimodal profiling of pediatric T-ALL samples. Bulk RNA sequencing of 1,335 primary tumors revealed that CD38 expression varies across genomic and immunophenotypic subtypes in T-ALL. Flow cytometry of 150 primary samples and CITE-sequencing of 40 cases demonstrated broad surface expression of CD38. A transcription factor CRISPR-screen identified RUNX1, RUNX3, and TP53 as candidate positive regulators of CD38. Metabolomic profiling of cell lines further revealed disruption of the polyamine pathway following CD38 perturbation. Supporting this finding, co-targeting CD38 with difluoromethylornithine (DFMO), a polyamine metabolism disruptor, improved survival in preclinical models. Across transcriptomic datasets, including primary tumors, cell lines, and patient-derived xenograft models, IL32 expression consistently decreased following CD38 loss or negativity, supporting an association between CD38 and inflammatory signaling pathways. Additionally, CD38 and LCK expression were positively correlated across majority of genomic subtypes, implicating SRC kinase signaling. Consistent with this, daratumumab in cell lines increased LCK phosphorylation, and combination therapy with dasatinib improved survival compared to monotherapy. Collectively, these findings define previously unrecognized interactions between CD38 and targetable pathways and genes in T-ALL and identify rational combinatorial strategies to enhance CD38-directed therapies and reduce relapse risk.
- Open Access
- 26 January 2026
- Published by Aboutscience Srl in Journal of Circulating Biomarkers
- Vol. 15 (1) , 69-77
Circulating free and low-density lipoprotein-bound GD2 can compete in vitro with neuroblastoma cells for binding therapeutic anti-GD2 antibodies
Introduction: GD2 is a ganglioside expressed on neuroblastoma cell membranes and shed into the circulation, where it primarily circulates bound to low-density lipoprotein (LDL). We questioned whether LDL-bound GD2 could interfere with the binding of therapeutic anti-GD2 monoclonal antibodies (like dinutuximab) to neuroblastoma cells.Methods: The GD2-expressing neuroblastoma cell line IMR5 was stained with an anti-GD2 antibody tagged with allophycocyanin (APC) at the lowest possible saturating concentration, and mean fluorescence intensity was measured by flow cytometry after in vitro exposure to GD2-LDL or free GD2 at multiple concentrations. Control experiments assessed the ability of GD2-expressing and GD2-non-expressing cells to compete for anti-GD2-APC antibodies with IMR5 cells.Results: Free and LDL-bound GD2 reduced anti-GD2-APC antibodies’ binding to IMR5 cells in vitro in a concentration-dependent manner. At physiologically relevant concentrations, LDL-bound GD2 blocked antibody binding to IMR5 to a greater extent than free GD2, including at 100 nM, a concentration below median GD2 concentrations in patients with high-risk neuroblastoma. At higher concentrations, LDL-bound GD2 inhibited antibody binding to IMR5 by up to 92.6%, whereas the same concentration of free GD2 only decreased antibody binding by 56.6%Conclusions: At concentrations found in patients with high-risk neuroblastoma, both free GD2 and LDL-bound GD2 blocked anti-GD2 antibody binding to neuroblastoma cells. These data suggest that circulating GD2-LDL could impact the efficacy of therapeutic anti-GD2 antibodies administered to patients with a high disease burden during induction therapy or at relapse and may have therapeutic implications for GD2-directed adoptive cellular therapies.
- 26 January 2026
- Published by Aboutscience Srl in Journal of Circulating Biomarkers
- Vol. 15 (1) , 69-77
Open AccessCirculating free and low-density lipoprotein-bound GD2 can compete in vitro with neuroblastoma cells for binding therapeutic anti-GD2 antibodies
Introduction: GD2 is a ganglioside expressed on neuroblastoma cell membranes and shed into the circulation, where it primarily circulates bound to low-density lipoprotein (LDL). We questioned whether LDL-bound GD2 could interfere with the binding of therapeutic anti-GD2 monoclonal antibodies (like dinutuximab) to neuroblastoma cells.Methods: The GD2-expressing neuroblastoma cell line IMR5 was stained with an anti-GD2 antibody tagged with allophycocyanin (APC) at the lowest possible saturating concentration, and mean fluorescence intensity was measured by flow cytometry after in vitro exposure to GD2-LDL or free GD2 at multiple concentrations. Control experiments assessed the ability of GD2-expressing and GD2-non-expressing cells to compete for anti-GD2-APC antibodies with IMR5 cells.Results: Free and LDL-bound GD2 reduced anti-GD2-APC antibodies’ binding to IMR5 cells in vitro in a concentration-dependent manner. At physiologically relevant concentrations, LDL-bound GD2 blocked antibody binding to IMR5 to a greater extent than free GD2, including at 100 nM, a concentration below median GD2 concentrations in patients with high-risk neuroblastoma. At higher concentrations, LDL-bound GD2 inhibited antibody binding to IMR5 by up to 92.6%, whereas the same concentration of free GD2 only decreased antibody binding by 56.6%Conclusions: At concentrations found in patients with high-risk neuroblastoma, both free GD2 and LDL-bound GD2 blocked anti-GD2 antibody binding to neuroblastoma cells. These data suggest that circulating GD2-LDL could impact the efficacy of therapeutic anti-GD2 antibodies administered to patients with a high disease burden during induction therapy or at relapse and may have therapeutic implications for GD2-directed adoptive cellular therapies.
- Open Access
- 24 September 2025
- Published by Springer Nature in Nature
- Vol. 646 (8085) , 707-715
Reprogramming neuroblastoma by diet-enhanced polyamine depletion
Neuroblastoma is a highly lethal childhood tumour derived from differentiation-arrested neural crest cells1,2. Like all cancers, its growth is fuelled by metabolites obtained from either circulation or local biosynthesis3,4. Neuroblastomas depend on local polyamine biosynthesis, and the inhibitor difluoromethylornithine has shown clinical activity5. Here we show that such inhibition can be augmented by dietary restriction of upstream amino acid substrates, leading to disruption of oncogenic protein translation, tumour differentiation and profound survival gains in the Th-MYCN mouse model. Specifically, an arginine- and proline-free diet decreases the amount of the polyamine precursor ornithine and enhances tumour polyamine depletion by difluoromethylornithine. This polyamine depletion causes ribosome stalling, unexpectedly specifically at codons with adenosine in the third position. Such codons are selectively enriched in cell cycle genes and low in neuronal differentiation genes. Thus, impaired translation of these codons, induced by combined dietary and pharmacological intervention, favours a pro-differentiation proteome. These results suggest that the genes of specific cellular programmes have evolved hallmark codon usage preferences that enable coherent translational rewiring in response to metabolic stresses, and that this process can be targeted to activate differentiation of paediatric cancers.
- 24 September 2025
- Published by Springer Nature in Nature
- Vol. 646 (8085) , 707-715
Open AccessReprogramming neuroblastoma by diet-enhanced polyamine depletion
Neuroblastoma is a highly lethal childhood tumour derived from differentiation-arrested neural crest cells1,2. Like all cancers, its growth is fuelled by metabolites obtained from either circulation or local biosynthesis3,4. Neuroblastomas depend on local polyamine biosynthesis, and the inhibitor difluoromethylornithine has shown clinical activity5. Here we show that such inhibition can be augmented by dietary restriction of upstream amino acid substrates, leading to disruption of oncogenic protein translation, tumour differentiation and profound survival gains in the Th-MYCN mouse model. Specifically, an arginine- and proline-free diet decreases the amount of the polyamine precursor ornithine and enhances tumour polyamine depletion by difluoromethylornithine. This polyamine depletion causes ribosome stalling, unexpectedly specifically at codons with adenosine in the third position. Such codons are selectively enriched in cell cycle genes and low in neuronal differentiation genes. Thus, impaired translation of these codons, induced by combined dietary and pharmacological intervention, favours a pro-differentiation proteome. These results suggest that the genes of specific cellular programmes have evolved hallmark codon usage preferences that enable coherent translational rewiring in response to metabolic stresses, and that this process can be targeted to activate differentiation of paediatric cancers.
- Open Access
- 22 April 2025
- Published by Wiley
Circulating Free and Low-Density Lipoprotein-Bound GD2 Can Compete with Neuroblastoma Cells for Binding Therapeutic Anti-GD2 Antibodies
Background: GD2 is a ganglioside that is expressed on the surface of neuroblastoma cells and shed into the circulation, where it primarily circulates bound to low density lipoprotein (LDL). We questioned whether free GD2 or GD2 bound to LDL could interfere with the binding of therapeutic anti-GD2 monoclonal antibodies like dinutuximab to neuroblastoma cells. Procedure: The GD2-expressing neuroblastoma cell line IMR5 was stained with an anti-GD2 antibody tagged with allophycocyanin (APC) at the lowest possible saturating concentration, and median fluorescence intensity was measured by flow cytometry after in vitro exposure to free GD2 or GD2 bound to LDL at concentrations of 0nM, 100nM, 1μM, and 5μM. Control experiments assessed the ability of cells with GD2 surface-expressed and GD2-non-expressing cells to compete for anti-GD2-APC antibodies with a population of 2 million IMR5 cells. Results: Free and LDL-bound GD2 reduced the binding of anti-GD2-APC antibodies to IMR5 cells in vitro in a concentration-dependent manner. At 100nM, which is below the median plasma GD2 concentration measured in patients with high-risk neuroblastoma prior to therapy, reduced antibody binding to IMR5 cells by 40%. Conclusions: At physiologic concentrations found in the plasma of patients with high-risk neuroblastoma, free GD2 and LDL-bound GD2 reduced the binding of anti-GD2 antibodies to GD2-expressing neuroblastoma cells, in vitro . This suggests that circulating GD2 could impact the efficacy of therapeutic anti-GD2 antibodies administered to patients with a high disease burden during induction therapy or at relapse.
- 22 April 2025
- Published by Wiley
Open AccessCirculating Free and Low-Density Lipoprotein-Bound GD2 Can Compete with Neuroblastoma Cells for Binding Therapeutic Anti-GD2 Antibodies
Background: GD2 is a ganglioside that is expressed on the surface of neuroblastoma cells and shed into the circulation, where it primarily circulates bound to low density lipoprotein (LDL). We questioned whether free GD2 or GD2 bound to LDL could interfere with the binding of therapeutic anti-GD2 monoclonal antibodies like dinutuximab to neuroblastoma cells. Procedure: The GD2-expressing neuroblastoma cell line IMR5 was stained with an anti-GD2 antibody tagged with allophycocyanin (APC) at the lowest possible saturating concentration, and median fluorescence intensity was measured by flow cytometry after in vitro exposure to free GD2 or GD2 bound to LDL at concentrations of 0nM, 100nM, 1μM, and 5μM. Control experiments assessed the ability of cells with GD2 surface-expressed and GD2-non-expressing cells to compete for anti-GD2-APC antibodies with a population of 2 million IMR5 cells. Results: Free and LDL-bound GD2 reduced the binding of anti-GD2-APC antibodies to IMR5 cells in vitro in a concentration-dependent manner. At 100nM, which is below the median plasma GD2 concentration measured in patients with high-risk neuroblastoma prior to therapy, reduced antibody binding to IMR5 cells by 40%. Conclusions: At physiologic concentrations found in the plasma of patients with high-risk neuroblastoma, free GD2 and LDL-bound GD2 reduced the binding of anti-GD2 antibodies to GD2-expressing neuroblastoma cells, in vitro . This suggests that circulating GD2 could impact the efficacy of therapeutic anti-GD2 antibodies administered to patients with a high disease burden during induction therapy or at relapse.
- Open Access
Reprogramming neuroblastoma by diet-enhanced polyamine depletion
Summary: Neuroblastoma is a highly lethal childhood tumor derived from differentiation-arrested neural crest cells 1,2 . Like all cancers, its growth is fueled by metabolites obtained from either circulation or local biosynthesis 3,4 . Neuroblastomas depend on local polyamine biosynthesis, with the inhibitor difluoromethylornithine showing clinical activity 5 . Here we show that such inhibition can be augmented by dietary restriction of upstream amino acid substrates, leading to disruption of oncogenic protein translation, tumor differentiation, and profound survival gains in the TH- MYCN mouse model. Specifically, an arginine/proline-free diet decreases the polyamine precursor ornithine and augments tumor polyamine depletion by difluoromethylornithine. This polyamine depletion causes ribosome stalling, unexpectedly specifically at adenosine-ending codons. Such codons are selectively enriched in cell cycle genes and low in neuronal differentiation genes. Thus, impaired translation of these codons, induced by the diet-drug combination, favors a pro-differentiation proteome. These results suggest that the genes of specific cellular programs have evolved hallmark codon usage preferences that enable coherent translational rewiring in response to metabolic stresses, and that this process can be targeted to activate differentiation of pediatric cancers. Graphical Highlights: - Extra-tumoral conversion of arginine feeds tumor ornithine via uptake from circulation in MYCN-neuroblastoma. - A proline and arginine free diet enhances pharmacological polyamine depletion via reduced ornithine substrate availability. - Polyamine depletion disrupts oncogenic translation to induce a pro-differentiation proteome causing neuroblast differentiation and prolonged survival in the TH-MYCN mouse model. - Genes of specific cellular programs have evolved codon usage preferences that enable coherent translational rewiring in response to metabolic stress, such as polyamine depletion.
Open AccessReprogramming neuroblastoma by diet-enhanced polyamine depletion
Summary: Neuroblastoma is a highly lethal childhood tumor derived from differentiation-arrested neural crest cells 1,2 . Like all cancers, its growth is fueled by metabolites obtained from either circulation or local biosynthesis 3,4 . Neuroblastomas depend on local polyamine biosynthesis, with the inhibitor difluoromethylornithine showing clinical activity 5 . Here we show that such inhibition can be augmented by dietary restriction of upstream amino acid substrates, leading to disruption of oncogenic protein translation, tumor differentiation, and profound survival gains in the TH- MYCN mouse model. Specifically, an arginine/proline-free diet decreases the polyamine precursor ornithine and augments tumor polyamine depletion by difluoromethylornithine. This polyamine depletion causes ribosome stalling, unexpectedly specifically at adenosine-ending codons. Such codons are selectively enriched in cell cycle genes and low in neuronal differentiation genes. Thus, impaired translation of these codons, induced by the diet-drug combination, favors a pro-differentiation proteome. These results suggest that the genes of specific cellular programs have evolved hallmark codon usage preferences that enable coherent translational rewiring in response to metabolic stresses, and that this process can be targeted to activate differentiation of pediatric cancers. Graphical Highlights: - Extra-tumoral conversion of arginine feeds tumor ornithine via uptake from circulation in MYCN-neuroblastoma. - A proline and arginine free diet enhances pharmacological polyamine depletion via reduced ornithine substrate availability. - Polyamine depletion disrupts oncogenic translation to induce a pro-differentiation proteome causing neuroblast differentiation and prolonged survival in the TH-MYCN mouse model. - Genes of specific cellular programs have evolved codon usage preferences that enable coherent translational rewiring in response to metabolic stress, such as polyamine depletion.
- Open Access
- 1 October 2011
- Published by Elsevier in Experimental Gerontology
- Vol. 46 (10) , 827-832
Increased iron supplied through Fet3p results in replicative life span extension of Saccharomyces cerevisiae under conditions requiring respiratory metabolism
- 1 October 2011
- Published by Elsevier in Experimental Gerontology
- Vol. 46 (10) , 827-832
Open AccessIncreased iron supplied through Fet3p results in replicative life span extension of Saccharomyces cerevisiae under conditions requiring respiratory metabolism